Search results for "Heros"

showing 10 items of 603 documents

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society …

2021

International audience; Background and aimsThis European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients.MethodsEvidence-based review.ResultsStatin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-h…

0301 basic medicinemedicine.medical_specialtyStatinSettore MED/09 - Medicina InternaCombination therapymedicine.drug_classHigh-risk2019 ESC/EAS Dyslipidaemia GuidelineLipid goal030204 cardiovascular system & hematologyTriglyceride03 medical and health sciences0302 clinical medicineCombined treatmentcardiovascular diseaseInternal medicinemedicineHumanstriglycerides2019 ESC/EAS Dyslipidaemia Guidelines; combination treatment; LDL cholesterol; triglycerides; lipid goals; high-risk; cardiovascular diseaselipid goalsbusiness.industryTask forceAnticholesteremic AgentsPCSK9Cholesterol LDL[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismAtherosclerosis2019 ESC/EAS Dyslipidaemia Guidelines3. Good health030104 developmental biologyDiabetes Mellitus Type 2Combination treatmentAtherosclerosiLDL cholesterolEuropean atherosclerosis societyKexinlipids (amino acids peptides and proteins)Proprotein Convertase 9Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessVery high risk
researchProduct

Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis

2018

AbstractAtherothrombosis is a leading cause of cardiovascular mortality and long-term morbidity. Platelets and coagulation proteases, interacting with circulating cells and in different vascular beds, modify several complex pathologies including atherosclerosis. In the second Maastricht Consensus Conference on Thrombosis, this theme was addressed by diverse scientists from bench to bedside. All presentations were discussed with audience members and the results of these discussions were incorporated in the final document that presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following five topics: 1. Risk factors, biomarkers and plaque inst…

0301 basic medicinemedicine.medical_specialtyanticoagulantsADJUST ANTIPLATELET THERAPYPERCUTANEOUS CORONARY INTERVENTION030204 cardiovascular system & hematologyarterial thrombosisArticleantiplatelet therapyACTIVATED PROTEIN-CRED-BLOOD-CELLS03 medical and health sciences0302 clinical medicineVITAMIN-K ANTAGONISTSInternal medicineatherothrombosisIschaemic strokeNONVALVULAR ATRIAL-FIBRILLATIONmedicinePlateletatrial fibrillationACUTE ISCHEMIC-STROKEcoagulationATOMIC-FORCE MICROSCOPYCardiovascular mortalityischaemic strokeAtomic force microscopybusiness.industryConsensus conferenceHematologymedicine.diseaseThrombosis030104 developmental biologymyocardial infarctionCoagulationplateletsDIRECT ORAL ANTICOAGULANTSCardiologyPosition paperSYMPTOMATIC VENOUS THROMBOEMBOLISMatherosclerosisbusiness
researchProduct

The TRPA1 Channel in the Cardiovascular System: Promising Features and Challenges.

2019

The transient receptor potential ankyrin 1 (TRPA1) channel is a calcium-permeable nonselective cation channel in the plasma membrane that belongs to the transient receptor potential (TRP) channel superfamily. Recent studies have suggested that the TRPA1 channel plays an essential role in the development and progression of several cardiovascular conditions, such as atherosclerosis, heart failure, myocardial ischemia–reperfusion injury, myocardial fibrosis, arrhythmia, vasodilation, and hypertension. Activation of the TRPA1 channel has a protective effect against the development of atherosclerosis. Furthermore, TRPA1 channel activation elicits peripheral vasodilation and induces a biphasic bl…

0301 basic medicinemedicine.medical_specialtyhypertensionheart failureVasodilationReviewTRPA1 Channelarrhythmia03 medical and health sciencesTransient receptor potential channel0302 clinical medicineInternal medicinemedicineTRPA1 channelAnkyrinPharmacology (medical)vasodilationchemistry.chemical_classificationPharmacologybusiness.industrylcsh:RM1-950food and beveragesmedicine.diseaseBlockademyocardial ischemia–reperfusion injurylcsh:Therapeutics. Pharmacology030104 developmental biologyBlood pressurechemistry030220 oncology & carcinogenesisHeart failureCardiologyMyocardial fibrosismyocardial fibrosisatherosclerosisbusinesspsychological phenomena and processesFrontiers in pharmacology
researchProduct

Aggravated Atherosclerosis and Vascular Inflammation With Reduced Kidney Function Depend on Interleukin-17 Receptor A and Are Normalized by Inhibitio…

2018

Visual Abstract

0301 basic medicinemedicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemIl17ra interleukin-17 receptor A (gene name)medicine.medical_treatmentInterleukin-17 receptormacrophage030204 cardiovascular system & hematologyLesionPRECLINICAL RESEARCH03 medical and health sciencesPCR polymerase chain reaction0302 clinical medicineInternal medicinemedicineMacrophageReceptorbusiness.industryCKD chronic kidney diseaseLDLr low-density lipoprotein receptorIL interleukinBlockadeEndothelial stem cell030104 developmental biologyEndocrinologyCytokinelcsh:RC666-701Interleukin 17medicine.symptomatherosclerosisCardiology and Cardiovascular Medicinebusinessinterleukin 17chronic kidney diseaseJACC: Basic to Translational Science
researchProduct

Srebf2 Locus Overexpression Reduces Body Weight, Total Cholesterol and Glucose Levels in Mice Fed with Two Different Diets

2020

Macronutrients represent risk factors for hyperlipidemia or diabetes. Lipid alterations and type 2 diabetes mellitus are global health problems. Overexpression of sterol regulatory element-binding factor (Srebf2) in transgenic animals is linked to elevated cholesterol levels and diabetes development. We investigated the impact of increased Srebf2 locus expression and the effects of control and high-fat, high-sucrose (HFHS) diets on body weight, glucose and lipid metabolisms in transgenic mice (S-mice). Wild type (WT) and S-mice were fed with both diets for 16 weeks. Plasma glucose, insulin and lipids were assessed (n = 25). Immunostainings were performed in liver, pancreas and fat (N = 10).…

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatment030209 endocrinology & metabolismlcsh:TX341-641Carbohydrate metabolismtransgenic miceArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineAdipocyteDiabetes mellitusHyperlipidemialipid metabolismmedicinecarbohydrate metabolismhigh-sucrose diethigh-fatNutrition and DieteticsCholesterolInsulinType 2 Diabetes MellituscholesterolLipid metabolismmedicine.diseaselipoproteins030104 developmental biologyEndocrinologychemistrylipids (amino acids peptides and proteins)atherosclerosissterol regulatory element-binding protein 2 (SREBP-2)lcsh:Nutrition. Foods and food supplyFood ScienceNutrients
researchProduct

Liver X Receptor–Mediated Induction of Cholesteryl Ester Transfer Protein Expression Is Selectively Impaired in Inflammatory Macrophages

2009

Objective— Cholesteryl ester transfer protein (CETP) is a target gene for the liver X receptor (LXR). The aim of this study was to further explore this regulation in the monocyte-macrophage lineage and its modulation by lipid loading and inflammation, which are key steps in the process of atherogenesis. Methods and Results— Exposure of bone marrow–derived macrophages from human CETP transgenic mice to the T0901317 LXR agonist increased CETP, PLTP, and ABCA1 mRNA levels. T0901317 also markedly increased CETP mRNA levels and CETP production in human differentiated macrophages, whereas it had no effect on CETP expression in human peripheral blood monocytes. In inflammatory mouse and human mac…

030204 cardiovascular system & hematologyMonocytesMice0302 clinical medicinepolycyclic compoundsPhospholipid Transfer ProteinsCells CulturedLiver X Receptors0303 health sciencesCell DifferentiationOrphan Nuclear ReceptorsUp-RegulationLipoproteins LDLmedicine.anatomical_structureABCG1Models Animalmonocytelipids (amino acids peptides and proteins)medicine.symptomCardiology and Cardiovascular MedicineOxidation-ReductionAgonistmedicine.medical_specialtymedicine.drug_classBlotting Westerncholesteryl ester transfer proteinMice TransgenicInflammationmacrophageBiology03 medical and health sciencesDownregulation and upregulationInternal medicineCholesterylester transfer proteinmedicineAnimalsHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyRNA MessengerLiver X receptorLiver X receptorProbability030304 developmental biologyMacrophagesMonocyteAtherosclerosisCholesterol Ester Transfer Proteinscarbohydrates (lipids)EndocrinologyGene Expression RegulationinflammationABCA1Immunologybiology.protein[SDV.AEN]Life Sciences [q-bio]/Food and NutritionArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Small, dense HDL display potent vasorelaxing activity, reflecting their elevated content of S1P

2016

IF 3.942; International audience

0303 health sciences03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemChemistryVasorelaxing activityFood science030204 cardiovascular system & hematology[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemCardiology and Cardiovascular MedicineAtherosclerosisS1P030304 developmental biology
researchProduct

The Role of Small, Dense LDL in Cardiovascular Risk: The Contributions of the Universities of Palermo and Zurich

2012

10265 Clinic for Endocrinology and Diabetology610 Medicine & healthatherosclerosis
researchProduct

Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective

2021

Dyslipidemia has been globally recognized, for almost seven decades, as one of the most important risk factors for the development and complications of atherosclerotic cardiovascular disease (ASCVD) [...]

2019-20 coronavirus outbreakFuture perspectiveLipid Metabolism DisorderCoronavirus disease 2019 (COVID-19)Atherosclerotic cardiovascular diseasebusiness.industryEndocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)medicine.diseaseBioinformaticsBiochemistryMicrobiologyQR1-502Editorialn/amedicinebusinessMolecular BiologyDyslipidemialipidi colesterolMetabolites
researchProduct

Atrial natriuretic factor, but not oxytocin, is present in atherosclerotic plaques of human common carotid arteries: an immunohistochemical in vivo s…

2009

ANPoxytocinatherosclerosishuman common carotid arteries.Settore BIO/16 - Anatomia Umana
researchProduct